An investigator-initiated study (IIS) is a clinical research study conceived, designed, and led by an independent researcher rather than by a pharmaceutical or device company. The researcher, often a physician or academic scientist, comes up with the research question, writes the study protocol, and directs the trial from start to finish. This stands in contrast to industry-sponsored trials, where a company designs the study and hires investigators to carry it out at various sites.
How IIS Differs From Industry-Sponsored Research
The core distinction is who has the original idea and who builds the protocol around it. In an investigator-initiated study, the researcher identifies a clinical question worth answering, perhaps noticing that an approved drug might work for a different condition, or that a particular patient population responds differently to standard treatment. They then design a study to test that hypothesis. In an industry-sponsored trial, a pharmaceutical or device company develops both the concept and the protocol, then recruits investigators to execute it.
The terminology can get confusing because “initiated” and “sponsored” refer to different things, even though people often use them interchangeably. “Initiated” describes who conceived the idea and developed the protocol. “Sponsored” is a regulatory term that refers to whoever takes on the legal and administrative responsibilities for the trial: registering it with authorities, monitoring it, and reporting safety data. These roles don’t always belong to the same person or organization. A researcher at a university hospital might initiate a study, but the university itself often assumes the regulatory role of sponsor. In that case, the accurate description is “investigator-initiated, institution-sponsored.” If an outside company provides funding on top of that, you have three distinct roles: investigator, sponsor, and funder.
What the Investigator Is Responsible For
When a researcher initiates a study, they take on a heavy set of obligations that would normally be handled by a company’s clinical operations team. According to FDA regulations, these responsibilities fall into several categories.
The investigator must personally conduct or directly supervise the investigation, ensure the study follows the approved protocol and all applicable regulations, and protect the rights, safety, and welfare of every participant. That means obtaining proper informed consent from each person before they enter the study, securing ethics board (IRB) approval before any research activities begin, and maintaining detailed case histories for every participant that document all observations and data collected during the trial.
Data management is a major part of the job. The investigator needs to keep records thorough enough that a regulator could reconstruct the entire study: what happened, to whom, and when. If the study involves an investigational drug, the investigator must track every dose, accounting for what was received, dispensed, returned, or destroyed. These records must be retained for at least two years after the drug is approved for marketing, or two years after the investigation is discontinued and the FDA is notified.
The investigator can delegate tasks to qualified team members, but they retain ultimate responsibility. They must keep a record of what was delegated, ensure the people doing the work are properly trained, and maintain oversight throughout the trial.
Safety Reporting Requirements
Safety reporting is one of the most time-sensitive obligations. When the investigator also serves as the sponsor (a “sponsor-investigator”), they must report serious adverse events to the FDA within strict deadlines. A serious adverse event is any reaction that results in death, a life-threatening situation, hospitalization, significant disability, or a birth defect.
If a serious and unexpected adverse reaction occurs, it must be reported to the FDA within 15 calendar days. If the reaction is fatal or life-threatening, the deadline shrinks to 7 calendar days. Any follow-up information about a previously reported event must also be submitted within 15 days of becoming available. These reports are filed on specific FDA forms and must be clearly labeled by type: “IND safety report,” “7-day IND safety report,” or “Follow-up IND safety report.”
These are the same timelines that large pharmaceutical companies follow, but a sponsor-investigator typically has far fewer staff to manage the reporting process, which makes it one of the more demanding aspects of running an IIS.
Funding and Industry Support
One of the biggest practical challenges for investigator-initiated studies is funding. Most independent researchers don’t have the budget to run a clinical trial on their own. Trials require biostatisticians, data managers, regulatory specialists, and sometimes years of patient follow-up.
To bridge this gap, many researchers seek partial support from pharmaceutical companies. This support commonly takes the form of grants or provision of the study drug at no cost. Some companies have formal IIS grant programs listed on their websites where investigators can submit proposals. However, the relationship can be complicated. Companies sometimes limit their support specifically to avoid being classified as the study’s sponsor, which would trigger a different set of regulatory responsibilities. In some cases, a company will supply the drug but decline to cover other costs like participant compensation, precisely because broader financial involvement could blur the line between funding and sponsoring.
Government grants, institutional funds, and nonprofit foundations are other common funding sources. Many academic medical centers have research support offices that help investigators identify funding opportunities and develop competitive proposals.
The Study Lifecycle
An investigator-initiated study typically moves through six stages, though the exact process varies by institution.
- Proposal development: The investigator refines the research question, study design, hypothesis, methodology, timeline, and budget. A feasibility assessment helps determine whether the study can realistically be completed at the proposed site with available resources.
- Funding: The completed proposal is submitted to one or more funding sources for review.
- Study startup: Once funded, the team develops the IRB protocol, consent forms, recruitment materials, and contracts with any outside vendors. This phase typically takes three to four months.
- Study activation: After IRB approval and contract execution, the team completes training and develops study manuals detailing all methods and procedures.
- Participant enrollment: The study goes live. The team screens, consents, and enrolls participants according to the protocol.
- Data analysis and dissemination: Biostatisticians analyze the collected data, and the investigator publishes or presents the findings.
Before any of this begins, the investigator must complete human subjects research training, such as the CITI (Collaborative Institutional Training Initiative) program.
Common Obstacles
The same qualities that make IIS valuable, independence and scientific curiosity, also create practical difficulties. The average investigator may lack expertise in one or more areas essential to running a trial: regulatory submissions, biostatistics, data management, or contract negotiation. Unlike a pharmaceutical company with dedicated departments for each function, an academic investigator often has to learn these skills or find collaborators who have them.
Funding uncertainty compounds the problem. Even when a company provides partial support, the investigator may need to piece together multiple funding sources, each with its own reporting requirements and restrictions. Patient recruitment is another persistent challenge, as independent investigators rarely have the recruitment infrastructure that large companies can deploy across dozens of sites simultaneously.
Despite these hurdles, investigator-initiated studies play a critical role in medical research. They explore questions that companies may have no commercial incentive to study, such as comparing existing treatments head-to-head, testing drugs in underserved populations, or investigating off-label uses. The research questions come from clinical observation rather than a business strategy, which often makes them directly relevant to everyday patient care.
Intellectual Property and Data Ownership
Who owns the results of an investigator-initiated study depends on the agreements in place before the research begins. Under U.S. federal contracting rules, a contractor (which can include a university or research institution) generally retains ownership of any inventions that arise from federally funded research. The government, in return, gets a permanent, royalty-free license to use the invention. If the institution fails to disclose an invention or file patent applications within required timeframes, the funding agency can request that ownership be transferred.
When industry funding is involved, the terms are negotiated in the study contract. Investigators and their institutions should clarify data ownership, publication rights, and patent rights before accepting any funding. A common point of negotiation is whether the investigator has the right to publish findings independently, regardless of whether the results are favorable to the funder’s product. Protecting this right is essential to maintaining the scientific independence that defines an IIS in the first place.